VTRS changes
Pick any two versions below to diff them.
- Price
- $20.67 → $19.63(−5.0%)
- Recent events
- Nov added: 17, 2026: Viatris completed its purchase of Pacira BioSciences on 17 November 2026. Holders of about 66.46% of Pacira shares tendered them at $36.50 per share in cash. The total price is about $1.69 billion, paid with cash and short-term loans. Nov 5, 2026: Viatris reported Q3 2026 results. Revenue was $3.75 billion, adjusted EBITDA was $1.20 billion, adjusted EPS was $0.71 and the GAAP net loss was $325 million because of a higher tax charge. It raised the midpoints of its 2026 guidance to revenue of $14.7 billion to $14.9 billion, adjusted EBITDA of $4.45 billion to $4.55 billion and adjusted EPS of $2.56 to $2.63. It said that supply constraints cost about $100 million of revenue in Q3 and will cost about $100 million in Q4. Oct 30, 2026: Viatris started its tender offer for Pacira BioSciences at $36.50 per share in cash, an equity value of about $1.65 billion. It expects the purchase to close by the end of November 2026. Oct 8, 2026: Viatris agreed to buy Pacira BioSciences, a maker of non-opioid pain medicines, in a merger agreement for $36.50 per share in cash. Jul 1, 2026: Viatris signed a new ¥40,000,000,000 unsecured term loan facility with Mizuho Bank. It repays the earlier loan of the same size from 2021. Jun 17, 2026: Viatris sold €650 million of 4.250% senior notes due 2033. It used the proceeds for the repayment of $1.675 billion of 3.950% senior notes that matured in 2026.